Respiratory syncytial virus infections: characteristics and treatment

Area of Science:

• Pediatrics
• Virology
• Infectious Diseases

Background:

• Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections in children worldwide.
• Current management relies on supportive care, with limited effective antiviral or anti-inflammatory options.
• Existing preventative measures like palivizumab are restricted to high-risk infants and face cost-effectiveness challenges.

Purpose of the Study:

• To review the history, epidemiology, and clinical aspects of RSV infections in children.
• To evaluate current and potential therapeutic and prophylactic strategies for RSV.
• To highlight the ongoing challenges in developing effective treatments and vaccines.

Main Methods:

• This is a review article, synthesizing existing literature on RSV.
• Information was gathered on epidemiology, clinical manifestations, and treatment options.
• Current and experimental therapies, as well as preventative measures, were assessed.

Main Results:

• No definitive cure for RSV infection exists; palliative treatments like oxygen and bronchodilators are common.
• Adrenaline shows promise over selective beta(2)-adrenoceptor agonists; corticosteroid efficacy is debated.
• Inhaled ribavirin is approved but restricted; palivizumab is the only licensed preventative for high-risk infants.
• Development of safe and effective RSV vaccines is ongoing but not yet realized.

Conclusions:

• Effective treatments and preventative strategies for RSV in children remain a significant unmet medical need.
• Further research is crucial for developing novel therapeutics and broadly applicable vaccines.
• Addressing the challenges in RSV management is essential for reducing childhood morbidity and mortality.